Shares Outstanding Shares Outstanding n/a Close	10.83M
Shares Change (YoY) Shares Change (YoY) n/a Close	931.97%
Shares Change (QoQ) Shares Change (QoQ) n/a Close	1.99%
Owned by Institutions (%) Owned by Institutions (%) n/a Close	71.91%
Shares Floating Shares Floating n/a Close	8.61M
Failed to Deliver (FTD) Shares Failed to Deliver (FTD) Shares n/a Close	129
FTD / Avg. Volume FTD / Avg. Volume n/a Close	0.18%

Short Selling Information

The latest short interest is 46.91K, so 0.43% of the outstanding shares have been sold short.

Short Interest Short Interest n/a Close	46.91K
Short % of Shares Out Short % of Shares Out n/a Close	0.43%
Short % of Float Short % of Float n/a Close	0.44%
Short Ratio (days to cover) Short Ratio (days to cover) n/a Close	1

Valuation Ratios

The PE ratio is -1.72 and the forward PE ratio is -0.97. Avalo Therapeutics's PEG ratio is 0.02.

PE Ratio PE Ratio n/a Close	-1.72
Forward PE Forward PE n/a Close	-0.97
PS Ratio PS Ratio n/a Close	136.95
Forward PS Forward PS n/a Close	3.5
PB Ratio PB Ratio n/a Close	0.45
P/FCF Ratio P/FCF Ratio n/a Close	-1.23
PEG Ratio PEG Ratio n/a Close	0.02

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Avalo Therapeutics.

EV / Sales EV / Sales n/a Close	n/a
EV / EBITDA EV / EBITDA n/a Close	n/a
EV / EBIT EV / EBIT n/a Close	n/a
EV / FCF EV / FCF n/a Close	n/a

Financial Position

The company has a current ratio of 19.96, with a Debt / Equity ratio of 0.

Current Ratio Current Ratio n/a Close	19.96
Quick Ratio Quick Ratio n/a Close	19.96
Debt / Equity Debt / Equity n/a Close	0
Debt / EBITDA Debt / EBITDA n/a Close	-0.01
Debt / FCF Debt / FCF n/a Close	-0.01
Interest Coverage Interest Coverage n/a Close	0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity Return on Equity n/a Close	n/a
Return on Assets Return on Assets n/a Close	n/a
Return on Invested Capital Return on Invested Capital n/a Close	n/a
Revenue Per Employee Revenue Per Employee n/a Close	$19,173.91
Profits Per Employee Profits Per Employee n/a Close	$-1,527,347.83
Employee Count Employee Count n/a Close	23
Asset Turnover Asset Turnover n/a Close	0
Inventory Turnover Inventory Turnover n/a Close	n/a

Taxes

Income Tax Income Tax n/a Close	114K
Effective Tax Rate Effective Tax Rate n/a Close	-0.33%

Stock Price Statistics

The stock price has increased by -64.17% in the last 52 weeks. The beta is 0.71, so Avalo Therapeutics's price volatility has been higher than the market average.

Beta Beta n/a Close	0.71
52-Week Price Change 52-Week Price Change n/a Close	-64.17%
50-Day Moving Average 50-Day Moving Average n/a Close	4.44
200-Day Moving Average 200-Day Moving Average n/a Close	7.82
Relative Strength Index (RSI) Relative Strength Index (RSI) n/a Close	54.24
Average Volume (20 Days) Average Volume (20 Days) n/a Close	73,562

Income Statement

In the last 12 months, Avalo Therapeutics had revenue of 441K and earned -35.13M in profits. Earnings per share was -4.32.

Revenue Revenue n/a Close	441K
Gross Profit Gross Profit n/a Close	807K
Operating Income Operating Income n/a Close	-68.51M
Net Income Net Income n/a Close	-35.13M
EBITDA EBITDA n/a Close	-68.34M
EBIT EBIT n/a Close	-68.51M
Earnings Per Share (EPS) Earnings Per Share (EPS) n/a Close	-4.32

Full Income Statement

Balance Sheet

The company has 134.55M in cash and 568K in debt, giving a net cash position of 133.98M.

Cash & Cash Equivalents Cash & Cash Equivalents n/a Close	134.55M
Total Debt Total Debt n/a Close	568K
Net Cash Net Cash n/a Close	133.98M
Retained Earnings Retained Earnings n/a Close	-370.26M
Total Assets Total Assets n/a Close	138.52M
Working Capital Working Capital n/a Close	121.33M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -49.06M and capital expenditures 0, giving a free cash flow of -49.06M.

Operating Cash Flow Operating Cash Flow n/a Close	-49.06M
Capital Expenditures Capital Expenditures n/a Close	n/a
Free Cash Flow Free Cash Flow n/a Close	-49.06M
FCF Per Share FCF Per Share n/a Close	-6.04

Full Cash Flow Statement

Margins

Gross margin is 182.99%, with operating and profit margins of -15535.6% and -7965.76%.

Gross Margin Gross Margin n/a Close	182.99%
Operating Margin Operating Margin n/a Close	-15535.6%
Pretax Margin Pretax Margin n/a Close	-7939.91%
Profit Margin Profit Margin n/a Close	-7965.76%
EBITDA Margin EBITDA Margin n/a Close	-15497.28%
EBIT Margin EBIT Margin n/a Close	-15535.6%
FCF Margin FCF Margin n/a Close	-11123.81%

Dividends & Yields

AVTX does not appear to pay any dividends at this time.

Dividend Per Share Dividend Per Share n/a Close	n/a
Dividend Yield Dividend Yield n/a Close	n/a
Dividend Growth (YoY) Dividend Growth (YoY) n/a Close	n/a
Payout Ratio Payout Ratio n/a Close	n/a
Earnings Yield Earnings Yield n/a Close	n/a
FCF Yield FCF Yield n/a Close	n/a

Dividend Details

Analyst Forecast

The average price target for AVTX is $30, which is 534.2% higher than the current price. The consensus rating is "Buy".

Price Target Price Target n/a Close	$30
Price Target Difference Price Target Difference n/a Close	534.2%
Analyst Consensus Analyst Consensus n/a Close	Buy
Analyst Count Analyst Count n/a Close	6

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value Lynch Fair Value n/a Close	n/a
Lynch Upside Lynch Upside n/a Close	n/a
Graham Number Graham Number n/a Close	n/a
Graham Upside Graham Upside n/a Close	n/a

Stock Splits

The last stock split was on Dec 29, 2023. It was a backward split with a ratio of 1:240.

Last Split Date Last Split Date n/a Close	Dec 29, 2023
Split Type Split Type n/a Close	backward
Split Ratio Split Ratio n/a Close	1:240

Scores

Altman Z-Score Altman Z-Score n/a Close	-2.16
Piotroski F-Score Piotroski F-Score n/a Close	3